Clinical Trials Browser

Phase 2/3 × INDUSTRY × sintilimab × Clear all

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular